Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NXGL
NXGL logo

NXGL Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.624
Open
0.610
VWAP
0.61
Vol
43.42K
Mkt Cap
5.48M
Low
0.600
Amount
26.41K
EV/EBITDA(TTM)
--
Total Shares
9.13M
EV
7.93M
EV/OCF(TTM)
--
P/S(TTM)
0.43
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.
Show More

Events Timeline

(ET)
2026-05-19
09:20:00
NexGel Reports Clinical Study Data Showing 37.2% Reduction in Hair Density
select
2026-04-27 (ET)
2026-04-27
09:20:00
NexGel Appoints Ian Blackman as CFO
select
2026-04-21 (ET)
2026-04-21
09:30:00
NexGel Completes Acquisition of Biomaterials from Celularity
select
2026-03-12 (ET)
2026-03-12
09:00:00
NexGel Acquires Celularity Biomaterials for $15 Million
select
2026-03-12
08:40:00
Celularity Signs Strategic Partnership with NEXGEL
select
2026-03-10 (ET)
2026-03-10
08:50:00
NexGel Signs Agreement to Acquire Celularity's Regenerative Biomaterials
select
2026-02-10 (ET)
2026-02-10
09:10:00
NEXGEL Announces $1.797M Financing for Potential Acquisition
select
2025-12-16 (ET)
2025-12-16
08:10:00
NEXGEL Announces Strategic Investment in NexGelRx
select
2025-12-11 (ET)
2025-12-11
08:20:00
NEXGEL Spins Off Drug Delivery Assets into NexGelRx
select

News

seekingalpha
9.5
05-15seekingalpha
NEXGEL Reports Q1 Earnings Miss
  • Earnings Performance: NEXGEL reported a Q1 GAAP EPS of -$0.11, missing expectations by $0.04, indicating ongoing pressure on profitability that could undermine investor confidence.
  • Revenue Decline: The company posted revenues of $2.65M, a 5.7% year-over-year decrease, falling short of expectations by $1.26M, reflecting challenges from weak market demand and intensified competition.
  • Cash Flow Situation: As of March 31, 2026, and December 31, 2025, the company had no cash equivalents, indicating increased liquidity risk that may limit future operational and investment capabilities.
  • Future Outlook: Despite the current financial setbacks, NEXGEL anticipates pro forma annual revenue of approximately $35M following the acquisition of Celularity's wound care segment, showcasing potential in strategic transformation.
Newsfilter
5.0
05-13Newsfilter
NEXGEL Appoints New VP of Sales to Drive BIONX Surgical Division Growth
  • Key Appointment: NEXGEL has appointed Dave Hazard as Vice President of Sales for BIONX Surgical, leveraging over 13 years of sales leadership in biologics to drive commercial growth in the newly formed division.
  • Sales Infrastructure Development: Hazard successfully built a salesforce of over 400 representatives at Nuo Therapeutics and secured a white label partnership with Smith+Nephew, showcasing his ability to establish scalable sales infrastructure that will underpin revenue growth for BIONX Surgical.
  • Strategic Partnerships: His experience at Arthrex, where he led a biologics business generating over $50 million annually, positions him well to enhance BIONX Surgical's competitive edge, as Arthrex is also a current strategic partner.
  • Product Innovation and Market Opportunities: Hazard noted that NEXGEL and BIONX Surgical possess a world-class portfolio with several new products in the pipeline, which are expected to drive strong market demand across sports medicine, orthopedics, and wound care sectors.
Newsfilter
9.5
05-12Newsfilter
NEXGEL to Report Q1 2026 Financial Results on May 15
  • Earnings Release Schedule: NEXGEL will report its financial results for Q1 2026 on May 15, 2026, providing insights into the company's performance in healthcare and consumer products, which is expected to deliver critical financial data and market outlook for investors.
  • Conference Call Timing: Following the earnings release, the company will host a conference call at 12:00 P.M. ET on the same day, allowing investors to dial in at 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) to receive real-time updates on the company's latest developments.
  • Replay Service: For those unable to attend the live call, NEXGEL offers a replay service available until May 29, 2026, accessible by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International), ensuring widespread dissemination of information.
  • Company Background: NEXGEL is a leading provider of healthcare and consumer products, specializing in ultra-gentle, high-water-content hydrogel products, with over 20 years of R&D and manufacturing experience, featuring brands like SilverSeal® and Hexagels®, showcasing its strong competitive position in the industry.
Newsfilter
5.0
04-27Newsfilter
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
  • Executive Appointment: NEXGEL has appointed Ian Blackman as Chief Financial Officer, leveraging his over 30 years of experience in luxury and consumer sectors to drive the integration of the Celularity acquisition, which is expected to enhance the company's financial foundation and operational efficiency.
  • Acquisition Integration Strategy: Blackman's appointment coincides with NEXGEL's final agreement with Celularity, anticipated to strengthen the company's market competitiveness and drive long-term shareholder value through the integration of regenerative medicine assets.
  • Performance Enhancement: During his tenure at McIntosh Group, Blackman successfully grew revenue by over 90% and EBITDA by over 335%, and his extensive financial management experience will provide robust support for NEXGEL's future growth.
  • Market Opportunities: NEXGEL's hydrogel technology platform and expanding commercial footprint present significant growth opportunities for stakeholders, and Blackman's addition will help optimize financial reporting processes and enhance the company's overall financial performance.
moomoo
5.0
04-27moomoo
NEXGEL NAMES IAN BLACKMAN AS CFO
  • New Appointment: A new Chief Financial Officer has been appointed at NEXGEL, a company focused on innovative gel technologies.

  • Leadership Impact: The appointment is expected to enhance the company's financial strategies and overall growth trajectory.

  • Company Background: NEXGEL specializes in developing advanced gel products for various applications, including healthcare and consumer markets.

  • Future Prospects: The new CFO's experience is anticipated to drive financial performance and support the company's expansion plans.

seekingalpha
8.5
04-22seekingalpha
NEXGEL's Acquisition of Celularity's Segment to Drive Profitability
  • Transaction Closure: NEXGEL has successfully acquired Celularity's degenerative wound segment, expected to boost annual revenue to approximately $35 million, marking a transformation into a more scalable and diversified medical technology company, enhancing market competitiveness.
  • New Division Launch: The company has established the BioNX Surgical division, focusing on advanced biomaterials for tendon repair, soft tissue reconstruction, and wound care, which is anticipated to drive commercial growth in new product lines.
  • Optimized Financing Structure: The transaction secured a $5.5 million investment through convertible notes with a conversion price of $0.60 and 50% warrant coverage, expected to enhance the company's financial stability and operational capabilities.
  • Positive Profit Outlook: Management anticipates that the acquisition will lead to immediate profitability, with EBITDA expected to be positive post-integration, reflecting strong market demand and growth potential in the new product lines.

Valuation Metrics

The current forward P/E ratio for Nexgel Inc (NXGL.O) is 1.38, compared to its 5-year average forward P/E of -13.39. For a more detailed relative valuation and DCF analysis to assess Nexgel Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.39
Current PE
1.38
Overvalued PE
7.41
Undervalued PE
-34.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
23.06
Current EV/EBITDA
-0.67
Overvalued EV/EBITDA
110.40
Undervalued EV/EBITDA
-64.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.25
Current PS
0.16
Overvalued PS
3.68
Undervalued PS
0.82

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

inom den amerikanska marknaden
Intellectia · 15 candidates
Market Cap: <= 1.50BPrice: <= $25.00Beta: HighRiskRsi 14: <= 45Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
SG logo
SG
Sweetgreen Inc
820.33M
NVX logo
NVX
NOVONIX Ltd
222.62M
LFMD logo
LFMD
LifeMD Inc
170.40M
TMCI logo
TMCI
Treace Medical Concepts Inc
166.30M
HFFG logo
HFFG
Hf Foods Group Inc
116.17M
PYXS logo
PYXS
Pyxis Oncology Inc
103.36M

Whales Holding NXGL

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Nexgel Inc (NXGL) stock price today?

The current price of NXGL is 0.6001 USD — it has decreased -0.17

What is Nexgel Inc (NXGL)'s business?

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.

What is the price predicton of NXGL Stock?

Wall Street analysts forecast NXGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXGL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nexgel Inc (NXGL)'s revenue for the last quarter?

Nexgel Inc revenue for the last quarter amounts to 2.65M USD, decreased -5.56

What is Nexgel Inc (NXGL)'s earnings per share (EPS) for the last quarter?

Nexgel Inc. EPS for the last quarter amounts to -0.11 USD, increased 22.22

How many employees does Nexgel Inc (NXGL). have?

Nexgel Inc (NXGL) has 19 emplpoyees as of June 01 2026.

What is Nexgel Inc (NXGL) market cap?

Today NXGL has the market capitalization of 5.48M USD.